Biotech | January 11, 2022
Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Intuitive Telepresence (ITP), facilitates remote learning, and encourages interaction and collaboration between surgeons without the need to travel
Cobas infinity edge is designed as an open platform, allowing healthcare professionals to easily access and adopt third-party innovators’ new digital tools and medically-relevant applications via the Roche digital marketplace
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
Dronedarone tablets USP, 400 mg have an estimated market size of US $ 500 million for twelve months ending September 2021 according to IQVIA
The HALO AP platform was developed by Indica Labs to address the specific needs of anatomic pathology labs by supporting a wide range of tissue-based workflows, including primary diagnosis, secondary consults, tumour boards, clinical trials, synoptic reporting, quantitative analytics, and AI
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
The drug is priced at Rs 2000 for a course of 40 tablets
Subscribe To Our Newsletter & Stay Updated
